icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Renewal of inclusion
Clinical Benefit
Substantial
The actual benefit of DOTAREM remains substantial.
Clinical Added Value
minor
DOTAREM offers a minor improvement in actual benefit (level IV) in terms of safety over gadolinium-based contrast media presenting a high (OMNISCAN, MAGNEVIST) or moderate (MULTIHANCE) risk of nephrogenic systemic fibrosis according to the European Medicines Agency classification.
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
4Exe0pBdGWNn9BFm